Early metabolic flare in squamous cell carcinoma after chemotherapy is a marker of treatment sensitivity in vitro

Nuclear Medicine and Molecular Imaging

Volumn 44, Issue 3, 2010, Pages 165-169

  Bjurberg, Maria ^a   Abedinpour, Parisa ^b   Brun, Eva ^a   Baldetorp, Bo ^a   Borgström, Per ^b   Wennerberg, Johan ^c   Kjellén, Elisabeth ^a,d  

^a LUND UNIVERSITY   (Sweden)

^b Vaccine Research Institute of San Diego   (United States)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d UMEÅ UNIVERSITY   (Sweden)

Author keywords

Chemotherapy; FDG PET; Flare; Fluorescence; NBDG; Squamous cell carcinoma

Indexed keywords

ARTICLE; CANCER CHEMOTHERAPY; CELL CYCLE ARREST; CELL METABOLISM; CELL SURVIVAL; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; EXPERIMENTAL STUDY; FLUORESCENCE MICROSCOPY; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

EID: 79952738194     PISSN: 18693474     EISSN: 18693482     Source Type: Journal    
DOI: 10.1007/s13139-010-0034-z     Document Type: Article

References (20)

1. Brun E, Kjellén E, Tennvall J, Ohlsson T, Sandell A, Perfekt R et al. (2002) FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck 24:27-35.
2. Hutchings M, Loft A, Hansen M, Pedersen LM, Buhl T, Jurlander J et al. (2006) FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107:52-9.
3. Ott K, Weber WA, Lordick F, Becker K, Busch R, Herrmann K et al. (2006) Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 24:4692-8.
4. Bjurberg M, Kjellén E, Ohlsson T, Bendahl PO, Brun E. (2009) Prediction of patient outcome with 2-deoxy-2-[18F]fluoro-Dglucose-positron emission tomography early during radiotherapy for locally advanced cervical cancer. Int J Gynecol Cancer 19:1600-5.
5. Spaepen K, Stroobants S, Dupont P, Bormans G, Balzarini J, Verhoef G et al. (2003) [(18)F]FDG PET monitoring of tumour response to chemotherapy: does [(18)F]FDG uptake correlate with the viable tumour cell fraction? Eur J Nucl Med Mol Imaging 30:682-8.
6. Dehdashti F, Flanagan F, Mortimer JE, Katzenellenbogen JA, Welch MJ, Siegel BA. (1999) Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med 26:51-6.
7. Mortimer JE, Dehdashti F, Siegel BA, Trinkaus K, Katzenellenbogen JA, Welch MJ. (2001) Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol 19:2797-803.
8. Aide N, Poulain L, Briand M, Dutoit S, Allouche S, Labiche A et al. (2009) Early evaluation of the effects of chemotherapy with longitudinal FDG small-animal PET in human testicular cancer xenografts: early flare response does not reflect refractory disease. Eur J Nucl Med Mol Imaging 36:396-405.
9. Aliaga A, Rousseau JA, Cadorette J, Croteau E, van Lier JE, Lecomte R et al. (2007) A small animal positron emission tomography study of the effect of chemotherapy and hormonal therapy on the uptake of 2-deoxy-2-[F-18]fluoro-D-glucose in murine models of breast cancer. Mol Imaging Biol 9:144-50.
10. Bjurberg M, Henriksson E, Brun E, Ekblad L, Ohlsson T, Brun A et al. (2009) Early changes in 2-deoxy-2-[18F]fluoro-D-glucose metabolism in squamous-cell carcinoma during chemotherapy in vivo and in vitro. Cancer Biother Radiopharm 24:327-32.
11. Cheng Z, Levi J, Xiong Z, Gheysens O, Keren S, Chen X et al. (2006) Near-infrared fluorescent deoxyglucose analogue for tumor optical imaging in cell culture and living mice. Bioconjug Chem 17:662-9.
12. O'ÑNeil RG, Wu L, Mullani N. (2005) Uptake of a fluorescent deoxyglucose analog (2-NBDG) in tumor cells. Mol Imaging Biol 7:388-92.
13. Gonzalez VM, Fuertes MA, Alonso C, Perez JM. (2001) Is cisplatin-induced cell death always produced by apoptosis? Mol Pharmacol 59:657-63.
14. Kubota R, Kubota K, Yamada S, Tada M, Ido T, Tamahashi N. (1994) Active and passive mechanisms of [fluorine-18] fluorodeoxyglucose uptake by proliferating and prenecrotic cancer cells in vivo: a microautoradiographic study. J Nucl Med 35:1067-75.
15. Eguchi Y, Shimizu S, Tsujimoto Y. (1997) Intracellular ATP levels determine cell death fate by apoptosis or necrosis. Cancer Res 57:1835-40.
16. Furuta M, Hasegawa M, Hayakawa K, Yamakawa M, Ishikawa H, Nonaka T et al. (1997) Rapid rise in FDG uptake in an irradiated human tumour xenograft. Eur J Nucl Med 24:435-8.
17. Kutler DI, Wong RJ, Schoder H, Kraus DH. (2006) The current status of positron-emission tomography scanning in the evaluation and follow-up of patients with head and neck cancer. Curr Opin Otolaryngol Head Neck Surg 14:73-81.
18. Weber WA. (2005) Use of PET for monitoring cancer therapy and for predicting outcome. J Nucl Med 46:983-95.
19. Farace P, D'Ambrosio D, Mergio F, Galiè M, Nanni C, Spinelli A et al. (2009) Cancer-associated stroma affects FDG uptake in experimental carcinomas. Implications for FDG-PET delineation of radiotherapy target. Eur J Nucl Med Mol Imaging 36:616-23.
20. Everitt S, Hicks RJ, Ball D, Kron K, Schneider-Kolsky M, Walter T et al. (2009) Imaging cellular proliferation during chemoradiotherapy: a pilot study of serial 18F-FLT positron emission tomography/computed tomography imaging for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 75:1098-104.